This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
ALBO Aperçu des actions
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.
| Score flocon de neige | |
|---|---|
| Évaluation | 1/6 |
| Croissance future | 2/6 |
| Performances passées | 0/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
Albireo Pharma, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$44.15 |
| Plus haut sur 52 semaines | US$45.23 |
| Plus bas sur 52 semaines | US$16.02 |
| Bêta | 1.04 |
| 1Variation sur 1 mois | -1.23% |
| Variation sur 3 mois | 85.66% |
| Variation sur 1 an | 66.73% |
| 3Variation sur 3 ans | 98.69% |
| Variation sur 5 ans | 28.53% |
| Évolution depuis l'introduction en bourse | 202.40% |
Nouvelles et mises à jour récentes
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Apr 26Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Albireo launches late-stage trial of odevixibat in Alagille Syndrome
Dec 17Albireo submits U.S. and European applications for odevixibat in liver disease
Dec 09Albireo Pharma (ALBO) Investor Presentation - Slideshow
Nov 17Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
Nov 13Rendement pour les actionnaires
| ALBO | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 1.2% | -3.0% | 0.9% |
| 1Y | 66.7% | 19.2% | 32.4% |
Rendement vs Industrie: ALBO exceeded the US Biotechs industry which returned 6.8% over the past year.
Rendement vs marché: ALBO exceeded the US Market which returned -9.2% over the past year.
Volatilité des prix
| ALBO volatility | |
|---|---|
| ALBO Average Weekly Movement | 27.3% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: ALBO's share price has been volatile over the past 3 months.
Volatilité au fil du temps: ALBO's weekly volatility has increased from 17% to 27% over the past year.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| n/a | 130 | Ron Cooper | www.albireopharma.com |
Albireo Pharma, Inc. Résumé des fondamentaux
| ALBO statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$921.13m |
| Bénéfices(TTM) | -US$131.14m |
| Recettes(TTM) | US$57.39m |
16.1x
Ratio P/S-7.0x
Ratio P/ELe site ALBO est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| ALBO compte de résultat (TTM) | |
|---|---|
| Recettes | US$57.39m |
| Coût des recettes | US$2.55m |
| Marge brute | US$54.84m |
| Autres dépenses | US$185.99m |
| Les revenus | -US$131.14m |
Derniers bénéfices déclarés
Sep 30, 2022
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -6.29 |
| Marge brute | 95.56% |
| Marge bénéficiaire nette | -228.51% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de ALBO?
Voir les performances historiques et les comparaisons